神经节苷脂联合左乙拉西坦治疗儿童病毒性脑炎继发癫痫的有效性及安全性分析  

Efficacy and Safety Analysis of Ganglioside Combined with Levetiracetam in the Treatment of Secondary Epilepsy in Children with Viral Encephalitis

作　　者：李传萍[1] 李华丽 LI Chuanping;LI Huali(Xihua County People's Hospital,Zhoukou Henan 466600)

机构地区：[1]西华县人民医院,河南周口466600

出　　处：《医学临床研究》2024年第9期1392-1394,共3页Journal of Clinical Research

摘　　要：【目的】探讨神经节苷脂联合左乙拉西坦治疗儿童病毒性脑炎继发癫痫的有效性及安全性。【方法】选取2021年1月至2023年1月本院收治的71例病毒性脑炎继发癫痫患儿,根据治疗方法不同将其分为对照组(n=35,常规治疗+左乙拉西坦)和观察组(n=36,在对照组治疗的基础上联合神经节苷脂)。比较两组的临床疗效、血清指标[神经元特异性烯醇化酶(NSE)、白细胞介素6(IL-6)、肿瘤坏死因子(TNF-α)]、脑脊液指标[肺表面活性物质相关蛋白D(SP-D)、半乳糖凝集素-9(Gal-9)],以及治疗后癫痫发作频率、安全性。【结果】治疗后,观察组临床有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组血清NSE、IL-6、TNF-α水平及脑脊液Gal-9水平低于治疗前,且观察组低于对照组(P<0.05);两组脑脊液SP-D水平高于治疗前,且观察组高于对照组(P<0.05)。出院后,观察组癫痫未发作或发作频率减少情况优于对照组(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。【结论】神经节苷脂联合左乙拉西坦治疗病毒性脑炎继发癫痫患儿的临床效果较好,可改善患儿免疫反应,有效降低患儿癫痫发作频率,安全性较好。【Objective】To investigate the efficacy and safety of ganglioside combined with levetiracetam in the treatment of secondary epilepsy in children with viral encephalitis.【Methods】A total of 71 children with secondary epilepsy caused by viral encephalitis admitted to our hospital from January 2021 to January 2023 were selected.According to the treatment method,they were divided into the control group(n=35,conventional treatment+levetiracetam)and the observation group(n=36,combined with ganglioside on the basis of treatment in the control group).The clinical efficacy,serum indicators[neuron specific enolase(NSE),serum interleukin-6(IL-6),tumor necrosis factor alpha(TNF-α)],cerebrospinal fluid indicators[pulmonary surfactant protein D(SP-D),galectin-9(Gal-9)],as well as the frequency and safety of epileptic seizures after treatment were compared between two groups of children.【Result】After treatment,the clinical effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of serum NSE,IL-6,TNF-α,and cerebrospinal fluid Gal-9 in both groups were lower than before treatment,and the observation group was lower than the control group(P<0.05);The levels of SP-D in the cerebrospinal fluid of both groups were higher than before treatment,and the observation group was higher than the control group(P<0.05).After discharge,the observation group showed better results than the control group in terms of no seizures or reduced seizure frequency(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).【Conclusion】The clinical effect of ganglioside combined with levetiracetam in the treatment of secondary epilepsy in children with viral encephalitis is good,improving their immune response,effectively reducing the frequency of seizures,and ensuring good safety.

关 键 词：脑炎 病毒性 癫痫 神经节苷脂类/治疗应用 左乙拉西坦/治疗应用 治疗结果 

分 类 号：R725.123[医药卫生—儿科]